eligibility_summary
Eligible: Adults ≥18 with DLBCL after failing prior therapy (CNS allowed), ECOG 0–3, measurable disease, adequate organs (bili ≤1.5×ULN, AST/ALT ≤2.5×, creat ≤1.5× & CrCl ≥60, INR/PT ≤1.5×), survival >3 mo, no prior bispecifics, negative pregnancy test & contraception. Exclude: CD20 loss, active HBV/HCV, recent therapy/trial/surgery/radiation, severe marrow, lung, heart (incl QTc>500/HTN), GI bleed risk, infections, ILD, HIV/syphilis, autoimmune disease (few exceptions), pregnancy/breastfeeding, allergy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single‑arm trial in relapsed/refractory DLBCL testing a combinatorial immuno‑radiotherapy: 1) Large‑fraction radiotherapy (hypofractionated RT, 5 Gy ×3): local cytotoxic DNA damage and immunogenic cell death, releasing tumor antigens and danger signals (in situ vaccination effect). 2) GM‑CSF (recombinant cytokine/growth factor): expands/recruits and activates dendritic cells and monocytes/macrophages, enhancing antigen presentation. 3) Lenalidomide (oral IMiD): binds cereblon E3 ligase causing Ikaros/Aiolos degradation, augments T‑ and NK‑cell activation and ADCC, modulates cytokines, anti‑angiogenic. 4) Glofitamab (CD20×CD3 T‑cell–engaging bispecific monoclonal antibody): redirects T cells via CD3 to lyse CD20+ B cells. Targets/pathways: CD20+ malignant B cells, T‑cell activation via CD3, antigen‑presenting cells (DCs/monocytes), NK cells, cereblon‑mediated ubiquitination, antigen presentation and cytotoxic T‑cell killing amplified by RT‑induced antigen release.